Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors - Wikidata - wikimedia - TriplyDB

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors

http://www.wikidata.org/entity/Q33388351

about

Heat shock proteins as danger signals for cancer detection Maximizing the Therapeutic Potential of HSP90 Inhibitors Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer Heat shock protein 90 inhibition: rationale and clinical potential.Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.Quantitatively integrating molecular structure and bioactivity profile evidence into drug-target relationship analysis A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer.Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer Potent antitrypanosomal activities of heat shock protein 90 inhibitors in vitro and in vivo.Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor.Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.Radioprotective effects of oral 17-dimethylaminoethylamino-17-demethoxygeldanamycin in mice: bone marrow and small intestine.Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease.Unfolded protein response in cancer: the physician's perspective The role of heat shock protein 90 in modulating ischemia-reperfusion injury in the kidney.Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.Overexpression of DJ-1 and HSP90α, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers.First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants.Hsp90 and angiogenesis in bone disorders--lessons from the avian growth plate.

P2860

Q24273349-71232A03-BF97-4AA6-BFFB-A99983E3BFA4 Q26798318-18CAAA02-96DB-4825-890F-9C667DD2A1AC Q27022514-A485F0B1-0479-4C5B-9BE3-9DE3550222E4 Q28304273-F1AC52B8-17C2-4264-9CB9-3688B8586EE0 Q28541342-15EE871D-15A5-45A7-BC24-4CD6B1C8B286 Q30418761-C749087B-95C7-4245-8681-504599091A52 Q33577386-33572CD9-C891-407A-93D4-309BC209B801 Q33688577-8EA0304B-EF0F-415B-AA88-460BB2855677 Q33825349-12FE601A-E672-4BDE-B29D-A2888178E37B Q34120364-C50608F7-AA7C-4AAA-88EF-D54F0F11D4A9 Q34258626-726CFC00-69F7-48A9-A83E-A2D8FC12BD92 Q34570770-971F54A0-DFC9-4B68-BB3B-1FECD0309B78 Q34636437-0E2F5776-7980-4E53-8DFC-41E16F8DB1D9 Q35166674-0887CCDC-63F3-41C6-89FE-4F7223D6168E Q35546764-EF012579-3D03-409C-BB4F-FFCA98318993 Q36060751-B5749C26-1047-4A6E-88AF-392DFF40BDDF Q36074307-5A5D9732-CD6B-4F96-9D3F-05FA433BB254 Q36490656-3EB584E7-9001-4590-A692-AB00A7BB017D Q36974927-16CCDB60-CD9D-43CE-B1C6-100A0A1BB927 Q37001967-F66FED77-B57C-4305-9A6F-1AD81475055A Q37213835-D262C2EF-48B7-4B88-9EBA-B7C0C2C9B1AE Q37286051-71B1A34C-25A7-4966-8063-646074482E17 Q37365958-6300BB11-D3F4-43F3-9909-C1CF32A925FD Q37717405-5760E5E1-309E-459D-83C9-8D3D3B62D2E9 Q37846249-A851CAA6-FC93-4A8D-82C6-31223CB61511 Q38033199-E115FBEB-A149-4D82-B49E-16823465B134 Q38769817-0F6DA74D-AEC0-4B10-816E-589E35095EA3 Q38834735-386CD6E8-5ABB-4B89-B40A-D99DA3191AC4 Q41660465-B34ABC3C-D378-4479-93E1-F64F81F641B4 Q41984466-89EE943F-CE86-4474-B8AA-9D36CCBD7BC4 Q48238685-E842EFFF-1B52-4A6B-ACA9-90E889856890 Q52327617-94B82290-E701-46D7-9F86-30EF6CC08ECB Q54590776-68E70981-D4E9-44BD-93F9-172B1BE8EE61

P2860

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors

http://www.wikidata.org/entity/Q33388351

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase I pharmacokinetic and ph ...... nts with advanced solid tumors

@ast

Phase I pharmacokinetic and ph ...... nts with advanced solid tumors

@en

type

label

Phase I pharmacokinetic and ph ...... nts with advanced solid tumors

@ast

Phase I pharmacokinetic and ph ...... nts with advanced solid tumors

@en

prefLabel

Phase I pharmacokinetic and ph ...... nts with advanced solid tumors

@ast

Phase I pharmacokinetic and ph ...... nts with advanced solid tumors

@en

P1433

Q33388351-F7989E1D-CA76-40FA-BFE7-090116EED7C1

P1476

Q33388351-07CA1869-8D28-4128-BF31-5C2806489342

P2093

Q33388351-07C1B75E-1B2A-433B-9412-4A26F11D75A3

Q33388351-12FF6F4F-96F7-4708-83A3-504563D60144

Q33388351-1B35E6E7-BA16-46FA-99DF-58AFEFC6733C

Q33388351-1BD9DD42-E984-47CC-9D9D-CA0B0CC6B186

Q33388351-1D34755F-7B78-4E09-8C37-3F0B7A12443B

Q33388351-2B78762C-562F-4281-8D17-39B36875C419

Q33388351-4A448301-8C13-4C28-984E-A28BC1F7FB12

Q33388351-604CC017-FC63-46B9-B986-C09DAC9BFDCA

Q33388351-EC62A5E1-A5EA-4042-BBBF-971C2D7F9F48

P2860

Q33388351-00E95CA6-59A0-4479-B5BD-A636EF82B6D9

Q33388351-223B6FEA-696E-4E40-B8B7-A030CDB5C1ED

Q33388351-32E17F28-340C-4E88-AA60-3FF270B1356A

Q33388351-4AC3CE6E-CD04-41DD-819A-D0D74799DECB

Q33388351-5173E727-496F-4FEC-8BCE-F3E684F6E7FE

Q33388351-55C5667C-5482-46C1-B573-88E3016DA467

Q33388351-6A168869-BD2E-417F-9265-1CCF9092C8AB

Q33388351-775D6ADB-7BC5-4C9F-92BF-76BD8B74E189

Q33388351-7A36BAC9-5CCD-4DCA-B01D-E55AD0E06C0F

Q33388351-7B28A756-4E72-492D-898C-AF4DBADFC08E

P304

Q33388351-ABB144E1-F4CD-4067-82FF-025E4DD2587C

P31

Q33388351-1644D389-7212-4A31-808A-993A610D2F44

P356

Q33388351-43C581C3-2C45-4C36-AEE5-73C59E7402A2

P407

Q33388351-604A2065-A117-48A4-B7C6-264ED25A16BB

P433

Q33388351-4C54FB56-983F-4B75-851E-159079BFFAB9

P478

Q33388351-506BF2C1-0E49-427F-A6CA-CC8A46ABD613

P50

Q33388351-DBAAA92F-3BAF-4B01-BC89-D2FDD81480D7

P577

Q33388351-C0FA6A79-9C8D-41A3-B158-C7C04598F375

P5875

Q33388351-A79EE6EC-6F53-47B4-BF19-E40FC425E8BD

P698

Q33388351-F3841C63-AC25-426A-9D85-E32F865C0144

P932

Q33388351-99D344CB-25ED-4144-86B1-1C49C2CC01E2

P356

JCO.2009.25.0415

P1433

Journal of Clinical Oncology

P1476

Phase I pharmacokinetic and ph ...... nts with advanced solid tumors

@en

P2093

Charles Erlichman

http://www.w3.org/2001/XMLSchema#string

Cynthia J TenEyck

http://www.w3.org/2001/XMLSchema#string

Cynthia Naret

http://www.w3.org/2001/XMLSchema#string

Julianne L Holleran

http://www.w3.org/2001/XMLSchema#string

Merrill J Egorin

http://www.w3.org/2001/XMLSchema#string

Ramesh K Ramanathan

http://www.w3.org/2001/XMLSchema#string

S Percy Ivy

http://www.w3.org/2001/XMLSchema#string

Scot C Remick

http://www.w3.org/2001/XMLSchema#string

Suresh S Ramalingam

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

The Hsp90 molecular chaperone: an open and shut case for treatment.

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

Heat shock protein 90 as a drug target: some like it hot.

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.

Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.

Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

P304

1520-1526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.25.0415

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41532438

http://www.w3.org/2001/XMLSchema#string

P698

20177028

http://www.w3.org/2001/XMLSchema#string

P932

2849772

http://www.w3.org/2001/XMLSchema#string